Drug treatment-related factors of inadequate seizure control

Epilepsy and Behavior

Volumn 13, Issue 3, 2008, Pages 545-548

  Handoko, Kim B ^a,b   Zwart van Rijkom, Jeannette E F ^c   Visee, Huib F ^d   Hermens, Walter A J J ^b   Hekster, Yechiel A ^e   Egberts, Toine C G ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Hospital Pharmacy 'Ziekenhuisapotheek Noordoost Brabant'   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d JEROEN BOSCH HOSPITAL   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antiepileptic drugs; Compliance; Epilepsy; Seizure control; Therapeutic drug monitoring

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT COMPLIANCE; SEIZURE;

ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CASE-CONTROL STUDIES; COMPLIANCE; CONFIDENCE INTERVALS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS; SEIZURES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 50849118782     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2008.04.007     Document Type: Article

References (30)

1. Mills N., Bachmann M., Harvey I., McGowan M., and Hine I. Patients' experience of epilepsy and health care. Fam Pract 14 (1997) 117-123
2. Hart Y.M., and Shorvon S.D. The nature of epilepsy in the general population: I. Characteristics of patients receiving medication for epilepsy. Epilepsy Res 21 (1995) 43-49
3. Moran N.F., Poole K., Bell G., et al. Epilepsy in the United Kingdom: seizure frequency and severity, anti-epileptic drug utilization and impact on life in 1652 people with epilepsy. Seizure 13 (2004) 425-433
4. Baker G.A., Jacoby A., Buck D., Stalgis C., and Monnet D. Quality of life of people with epilepsy: a European study. Epilepsia 38 (1997) 353-362
5. Brodie M.J., and French J.A. Management of epilepsy in adolescents and adults. Lancet 356 (2000) 323-329
6. Eeg-Olofsson O. Virological and immunological aspects of seizure disorders. Brain Dev 25 (2003) 9-13
7. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. October 2004 [cited 2007 December 18]. Available from: http://www.nice.org.uk/nicemedia/pdf/CG020NICEguideline.
8. Epilepsie: Richtlijnen voor diagnostiek en behandeling. January, 2006 [cited 2007 December 18]. Available from: http://www.neurologie.nl/uploads/136/454/richtlijn_epilepsie_definief_2.pdf.
9. Yukawa E. Optimisation of antiepileptic drug therapy: the importance of serum drug concentration monitoring. Clin Pharmacokinet 31 (1996) 120-130
10. Johannessen S.I., and Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?. Clin Pharmacokinet. 45 (2006) 1061-1075
11. Jones R.M., Butler J.A., Thomas V.A., Peveler R.C., and Prevett M. Adherence to treatment in patients with epilepsy: associations with seizure control and illness beliefs. Seizure 15 (2006) 504-508
12. Leppik I.E. Compliance during treatment of epilepsy. Epilepsia 29 Suppl. 2 (1988) S79-S84
13. Cramer J.A., Glassman M., and Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav 3 (2002) 338-342
14. Asadi-Pooya A.A. Drug compliance of children and adolescents with epilepsy. Seizure 14 (2005) 393-395
15. Handoko K.B., Zwart-van Rijkom J.E., Hermens W.A., Souverein P.C., and Egberts T.C. Changes in medication associated with epilepsy-related hospitalisation: a case-crossover study. Pharmacoepidemiol Drug Saf 16 (2007) 189-196
16. Patsalos P.N., Froscher W., Pisani F., and van Rijn C.M. The importance of drug interactions in epilepsy therapy. Epilepsia 43 (2002) 365-385
17. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 61 (2006) 246-255
18. Torta R., and Monaco F. Atypical antipsychotics and serotoninergic antidepressants in patients with epilepsy: pharmacodynamic considerations. Epilepsia 43 Suppl. 2 (2002) 8-13
19. Neels H.M., Sierens A.C., Naelaerts K., Scharpe S.L., Hatfield G.M., and Lambert W.E. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 42 (2004) 1228-1255
20. Johannessen S.I. Can pharmacokinetic variability be controlled for the patient's benefit? The place of TDM for new AEDs. Ther Drug Monit 27 (2005) 710-713
21. Steiner J.F., and Prochazka A.V. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 50 (1997) 105-116
22. Van Wijk B.L., Klungel O.H., Heerdink E.R., and de Boer A. Initial non-compliance with antihypertensive monotherapy is followed by complete discontinuation of antihypertensive therapy. Pharmacoepidemiol Drug Saf 15 (2006) 587-593
23. Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol 15 (2001) 405-417
24. Morris R.G., Black A.B., Harris A.L., Batty A.B., and Sallustio B.C. Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 46 (1998) 547-551
25. Glauser T.A., and Pippenger C.E. Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy. Epilepsia 41 Suppl. 8 (2000) S6-S15
26. Birnbaum A., Hardie N.A., Leppik I.E., et al. Variability of total phenytoin serum concentrations within elderly nursing home residents. Neurology 60 (2003) 555-559
27. Eadie M.J. Therapeutic drug monitoring: antiepileptic drugs. Br J Clin Pharmacol 52 Suppl. 1 (2001) 11-20S
28. Lammers M.W., Hekster Y.A., Keyser A., van Lier H., Meinardi H., and Renier W.O. Neither dosage nor serum levels of antiepileptic drugs are predictive for efficacy and adverse effects. Pharm World Sci 17 (1995) 201-206
29. Jannuzzi G., Cian P., Fattore C., et al., for the Italian TDM Study Group in Epilepsy. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. Epilepsia 41 (2000) 222-230
30. Woo E., Chan Y.M., Yu Y.L., Chan Y.W., and Huang C.Y. If a well-stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study. Epilepsia 29 (1988) 129-139